Dajun Pharmaceutical

Suzhou Dajun Pharmaceutical Technology (Dajun Biopharma) is a clinical-stage biopharmaceutical company based in the Suzhou Industrial Park, China. The company specializes in the research and development of innovative small molecule drugs, primarily focusing on high-impact indications in oncology and metabolic diseases. Dajun's leading clinical asset, DJ-001, is a selective inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for acute myeloid leukemia (AML) and solid tumors. Beyond its clinical programs, the company is advancing a robust preclinical pipeline, including DJ-005 for the treatment of nonalcoholic steatohepatitis (NASH). Led by a team of scientists with deep roots in global pharmaceutical R&D, Dajun is committed to bridging the gap between early-stage discovery and clinical success through advanced drug metabolism and design platforms.